No healthcare specialty has seen a faster increase in FDA and FTC enforcement over the last 18 months than weight loss clinics marketing GLP-1 receptor agonists - semaglutide, tirzepatide, liraglutide, and their compounded variants. The regulatory environment around GLP-1 is the most complex in healthcare advertising today because it overlays five distinct issues at once.
This post walks through that five-layer stack: drug identity, compounding rules, off-label use, outcome claims, and before/after photo compliance. If you run a weight loss or metabolic clinic marketing GLP-1 products, each layer has to be addressed separately.
Layer 1: Drug identity and name use
Novo Nordisk markets semaglutide under three brand names: Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral type 2 diabetes). Eli Lilly’s tirzepatide is branded Mounjaro (diabetes) and Zepbound (weight management). Using the branded name in your clinic’s marketing triggers trademark and regulatory issues.
The rules at a glance
- Never market a branded drug you don’t dispense. Using “Ozempic” in your copy implies you’re providing Ozempic.
- Never imply a compounded product is the branded product. Semaglutide compounded at a 503A or 503B pharmacy is NOT Ozempic. FDA treats conflating the two as a misbranding issue.
- Use the generic molecule name when describing compounded products.“Compounded semaglutide” is factually accurate and doesn’t step on trademark.
“Affordable Ozempic weight loss - $299/mo.”
“Medically supervised semaglutide weight loss program, using compounded semaglutide prepared by a state-licensed compounding pharmacy. This is not FDA-approved Ozempic or Wegovy.”
Why: Brand-name confusion is a federal issue on two tracks (FDA misbranding + Lanham Act trademark). The compliant version is explicit about the compounded status and the non-FDA-approved nature of the program.
Layer 2: Compounding rules
The FDA allows compounded versions of drugs under specific circumstances (503A for patient-specific prescriptions; 503B for outsourcing facilities). Compounded semaglutide marketing has its own set of FDA concerns:
- Drug-shortage status: Compounding of a drug on the FDA shortage list is permitted under specific rules; outside the shortage list, there are stricter constraints.
- Marketing to the general public:503A compounding is patient-specific and based on an individual prescription. Marketing “come get semaglutide” to the public blurs this line and is an FDA enforcement target.
- Product composition:Compounded products may include additives (B12, B-complex, etc.) that are NOT present in the branded drug. Marketing these as “the same as Ozempic, plus extras” is false equivalence.
“Our exclusive semaglutide+B12 formula - more effective than Ozempic.”
“A semaglutide formulation compounded to your individual prescription. Some programs include additional vitamin B12; this is an additive, not an FDA-evaluated enhancement to efficacy.”
Why: Never claim a compounded variant is “more effective” than the branded drug without head-to-head substantiation (which does not exist). Disclose additives as additives, not as efficacy enhancers.
Layer 3: Off-label indication use
Semaglutide is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management in patients meeting specific BMI criteria (Wegovy). Marketing semaglutide for weight loss in patients who don’t meet the Wegovy criteria is off-label use.
Off-label prescribing is legal for licensed physicians. Off-label marketing has significantly tighter rules. A clinic marketing semaglutide for weight loss without specifying the indication criteria is effectively promoting an unapproved use to the general public.
“Semaglutide weight loss program - lose 15% of your body weight in 6 months.”
“Medically supervised GLP-1-based weight loss program. A physician consultation will determine whether GLP-1 therapy is appropriate based on your BMI, medical history, and weight loss goals. FDA-approved indications for weight management apply to specific patient populations.”
Why: Don't publish outcome-specific weight-loss claims to the general public. Route the clinical decision to the physician consultation and flag that FDA-approved indications are population-specific.
Layer 4: Outcome claims
The weight loss industry has decades of FTC enforcement history around specific language. The agency has settled multiple cases against weight loss marketers for unsubstantiated claims including:
- Specific-pound or specific-percentage claims without substantiation.
- Before-and-after photo galleries implying typical outcomes.
- Testimonial-based outcome claims without typicality disclosure.
- “Guaranteed” weight loss language.
- Comparative claims (“better than diet and exercise”).
The FTC doesn’t care that GLP-1 drugs doproduce weight loss in clinical trials. The enforcement theory is about how the claim is presented in marketing - whether it’s substantiated for this specific product, this specific population, and this specific clinical context.
“Lose up to 30 lbs in 3 months, guaranteed.”
“Weight loss outcomes on GLP-1 therapy vary significantly by patient. In clinical trials of FDA-approved semaglutide for chronic weight management, the average weight loss was approximately 15% of body weight over 68 weeks in patients meeting specific criteria. Your results will depend on your starting point, adherence, and medical history.”
Why: Replace the outcome guarantee with honest clinical-trial-based language, specifying the population and timeframe. Long, specific, factual - and defensible.
Layer 5: Before-and-after photos
Before-and-after weight loss photos are the most regulated visual format in healthcare marketing. The FTC Endorsement Guides govern this entire category. See the before-and-after photos deep dive for the full protocol. For GLP-1 specifically:
- Typical-experience disclosure required on every photo presented as representative.
- Time frame must be disclosed.“Results in 90 days” requires that both photos were taken 90 days apart.
- Patient consent documentation must be retained.
- Diet-and-exercise qualifier:GLP-1 trial results assumed adherence to diet and exercise guidelines. Photos without that disclosure overclaim the drug’s solo contribution.
Social media and platform policy specifics
Meta, TikTok, and Google have all tightened their healthcare ad policies specifically around GLP-1 marketing in 2024–2025. Platform-level rejection happens before any regulator notices, but platform violations are often the evidence a regulator uses to build a case.
- Meta / Instagram: Weight loss claims with specific numerical outcomes are typically rejected. Testimonials with dramatic transformations often trigger policy review.
- TikTok: Healthcare products including GLP-1 are on a restricted category list. Brand-name drug references in organic content (not just ads) have triggered video removal.
- Google Ads: Prescription drug advertising is heavily restricted and typically requires certification (LegitScript for pharmacy-related advertising). Weight loss claims face additional scrutiny.
What a compliant GLP-1 program page looks like
- Landing hero:“Medically supervised weight loss program featuring GLP-1 therapy.” No brand names, no outcome numbers, no guarantees.
- Program description: Consultation process, BMI/ medical-history screening, prescription basis, follow-up cadence.
- What GLP-1 is: Educational content on the drug class. Disclose clearly if you use compounded semaglutide.
- Who it’s for:“A physician consultation determines whether GLP-1 therapy is appropriate for you.” Not “suitable for anyone who wants to lose weight.”
- Expected outcomes section: Cite clinical-trial ranges with population and timeframe qualifiers. Individual- variation disclosure prominent.
- Risks: Standard side-effect profile. Honest risk disclosure is both legally protective and trust-building.
- Testimonials (if any): Subjective-experience language, typical-experience disclosure, substantiation file.
- Pricing:Disclose compounded vs branded. Don’t position compounded as a “deal” on the branded drug.